Cidara Therapeutics (CDTX) Skyrockets 80% Today—What’s Fueling the Surge?
Cidara Therapeutics just pulled off a moonshot—its stock (CDTX) blasted 80% higher in a single trading session. Here's the breakdown.
Clinical Catalyst or Short Squeeze?
No major news hit the wires, but biotech traders aren't waiting for FDA paperwork. Either insiders know something we don't, or hedge funds just got caught with their shorts down—again.
Biotech's High-Stakes Casino
CDTX's wild ride proves one thing: the sector remains a playground for risk-hungry capital. When these binary bets pay off, they pay big. Today, shareholders are cashing in while Wall Street scrambles to justify the move.
Memo to retail investors: hope you got in before the algos did. These spikes rarely last—ask anyone who chased the last 'revolutionary' Phase 2 readout.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The big news here is that the clinical trial met its primary endpoint. Data from the study showed prevention efficacy of 57.7% from the 150 mg treatment, 61.3% from the 300 mg treatment, and 76.1% from the 450 mg treatment. Additionally, the study met all of its secondary endpoints, including efficacy at 37.8 degree and 37.2 degree Celsius temperature thresholds, and prevention efficacy maintenance of up to 28 weeks.
The positive results from this study sent shares of CDTX stock up 83.11% on Monday, extending its 86.18% 12-month rally and reversing a 21.8% year-to-date drop.
Is CDTX Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Cidara Therapeutics is Strong Buy, based on seven Buy ratings over the past three months. With that comes an average CDTX stock price target of $42.33, representing a potential 101.38% upside for the shares.
